- Home
- FNKO vs ABOS Comparison
FNKO vs ABOS Comparison
Compare FNKO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FNKO | ABOS |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 182.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FNKO | ABOS |
|---|---|---|
| Price | $5.54 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 809.0K | 285.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $908,209,000.00 | N/A |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $1.00 |
| 52 Week High | $6.09 | $3.60 |
Technical Indicators
Market Signals| Indicator | FNKO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 67.80 | 53.08 |
| Support Level | $2.92 | $2.15 |
| Resistance Level | $5.64 | $2.77 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 68.05 | 71.76 |
Price Performance
Historical ComparisonAbout FNKO Funko Inc.
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.